Department of Cardiovascular Medicine, Affiliated Haian Hospital of Nantong University, Nantong, China. Email:
Department of Cardiovascular Medicine, Affiliated Haian Hospital of Nantong University, Nantong, China.
Ann Palliat Med. 2021 Jan;10(1):97-103. doi: 10.21037/apm-20-2147.
Alprostadil can effectively dilate blood vessels, improve cardiac microcirculation, and reduce cardiac load. Tanshinone IIa injection can protect against atherosclerosis and reduce myocardial oxygen consumption. However, the effects of alprostadil combined with tanshinone IIa injection on microcirculation disorder, outcomes, and cardiac function in patients with acute myocardial infarction (AMI) after percutaneous coronary intervention (PCI) are still not fully clear.
A total of 300 AMI patients who underwent PCI in our hospital from January 2013 to June 2018 were randomly selected and divided into group A, B, C by using the random number table method, with 100 patients in each group. The group A was treated with alprostadil, the group B was treated with tanshinone IIa injection, and the group C was treated with alprostadil combined with tanshinone IIa injection. 7 days after treatment, the cardiac functions of all patients were observed by ultrasonic Doppler, as were the microcirculations by myocardial contrast echocardiography (MCE). The major adverse cardiac events (MACEs) in both groups were observed in the 12-month follow-up.
After treatment, the left ventricular end-diastolic diameter (LVEDD), end-diastolic left ventricular posterior wall thickness (LVPWD), left ventricular ejection fraction (LVEF), left ventricular end-systolic diameter (LVESD), interventricular septum thickness (IVST), and ratio of maximal early to late diastolic filling velocities (E/A) in the group C were superior to those in the group A and B, the differences were statistically significant (PP<0.05). After treatment, MCE showed that the Aβ value of the group aC was higher than that of the group A and B, the difference was statistically significant (P<0.05). The thrombolysis in myocardial infarction myocardial perfusion grade classification showed that the patients with grades 2‒3 were more abundant in the group C than the group A and B, the difference was statistically significant (PP<0.05). The incidences of MACEs, such as malignant arrhythmia, recurrent heart failure (HF), recurrent myocardial infarction, and death, in the group C were significantly lower than those in the group A and B (PP<0.05).
For AMI patients after PCI, alprostadil combined with tanshinone IIa injection can effectively improve microcirculation and ventricular remodeling, improve cardiac function and reduce the occurrence of MACEs. This combination can be widely used in clinical practice.
前列地尔能有效扩张血管,改善心肌微循环,降低心脏负荷。丹参酮ⅡA 注射液具有抗动脉粥样硬化、降低心肌耗氧量的作用。然而,前列地尔联合丹参酮ⅡA 注射液对急性心肌梗死(AMI)患者经皮冠状动脉介入治疗(PCI)后微循环障碍、预后及心功能的影响尚不完全清楚。
选取我院 2013 年 1 月至 2018 年 6 月收治的 300 例行 PCI 的 AMI 患者,采用随机数字表法分为 A、B、C 组,每组 100 例。A 组给予前列地尔治疗,B 组给予丹参酮ⅡA 注射液治疗,C 组给予前列地尔联合丹参酮ⅡA 注射液治疗。治疗 7d 后,采用超声多普勒观察所有患者的心功能,采用心肌声学造影(MCE)观察其微循环。随访 12 个月,观察两组主要不良心脏事件(MACEs)发生情况。
治疗后,C 组左心室舒张末期直径(LVEDD)、左心室舒张末期后壁厚度(LVPWD)、左心室射血分数(LVEF)、左心室收缩末期直径(LVESD)、室间隔厚度(IVST)及最大舒张早期与晚期充盈速度比值(E/A)均优于 A 组和 B 组,差异有统计学意义(PP<0.05)。治疗后,MCE 显示 C 组 Aβ值高于 A 组和 B 组,差异有统计学意义(P<0.05)。心肌梗死溶栓治疗血流分级显示,C 组 2~3 级患者较 A 组和 B 组更丰富,差异有统计学意义(PP<0.05)。C 组恶性心律失常、心力衰竭(HF)再发、再发心肌梗死和死亡等 MACEs 的发生率明显低于 A 组和 B 组(PP<0.05)。
对于 PCI 后的 AMI 患者,前列地尔联合丹参酮ⅡA 注射液能有效改善微循环和心室重构,改善心功能,降低 MACEs 发生率,该联合方案在临床上具有广泛的应用价值。